BIOXYTRAN INC - BIXT STOCK NEWS

Bioxytran (OTCQB: BIXT) has released a preprint article exploring the potential enhancement of cancer immunotherapy through galectin-3 modulation. The research focuses on improving Immune Checkpoint Inhibitors (ICIs) effectiveness in cancer treatment. Key findings show that high galectin-3 levels correlate with treatment failure, with 90% of Non-Small Cell Lung Cancer patients with elevated levels failing to respond after three treatments.

The study reveals that galectin-3 protein interferes with ICI therapy by occupying the antibody's PD-1 receptor binding site, preventing effective treatment. However, in vitro tests indicate that galectin-3 antagonists could potentially reverse this effect. The company also published a presentation on cancer metastasis, highlighting the 'Galectin Effect' as cancer's primary defense mechanism against immune response.

Bioxytran (OTCQB: BIXT) held a significant Techwatch Light meeting with BARDA, attracting over 65 government personnel from various agencies including CDMRP, NIAID, NIH, DTRA, and DoD. The company presented four key Areas of Interest: influenza antiviral, immune modulators for lung repair, solutions for uncontrolled hemorrhaging, and a versatile strategic therapeutic.

The meeting focused primarily on discussions about the influenza antiviral and Universal Oxygen Carrier. BARDA provided guidance on program qualification requirements and potential funding opportunities. The company received feedback on development stages and supporting data needed for specific programs, marking a strategic step toward securing government funding for clinical trial development.

Bioxytran (OTCQB:BIXT) has announced a significant breakthrough in virology, validated in a peer-reviewed journal article. The company's drug candidate, Prolectin-M, has shown effectiveness in stopping COVID-19 and other viruses by blocking galectin, a protein important for viral attachment to cells. This discovery, made using advanced Nuclear Magnetic Resonance (NMR) spectroscopy, could impact both the antiviral and vaccination markets, collectively valued at approximately $147 billion.

The study revealed that galectins, located on the virus's spike protein, are an excellent drug target due to their stability. This could lead to the development of broad-spectrum antivirals effective against various viruses. Bioxytran's CEO, Dr. David Platt, believes this discovery represents a new era in antiviral drug development, potentially revolutionizing the treatment of viral diseases and even chronic illnesses like cancer.

Bioxytran (OTCQB: BIXT) has formed a Joint Venture with the Heme Foundation to develop a Universal Oxygen Carrier (UOC) as an alternative to blood transfusions. The Foundation pledged up to $10 million for the project, with $2 million already invested in prototypes and compound development. Bioxytran retains all intellectual property rights, while the Foundation gains usage rights for blood transfusion applications.

The UOC, a hemoglobin-based oxygen carrier, is designed to be compatible with all blood types, pathogen-free, and shelf-stable at room temperature for 5+ years. It has shown promise in small-scale animal trials and is preparing for a large-scale toxicology study. This technology could revolutionize transfusion medicine, particularly in remote areas with blood supply infrastructure.

Bioxytran's Science Advisor, Prof. Avraham Mayevsky, has published a book titled Hyperbaric Oxygenation Mitochondrial Activity and Brain Physiological Functions. The book, available as an eBook or hardcover from Springer, delves into the impact of hyperbaric oxygen on brain functions, particularly mitochondrial activity.

Central to the book is the MDX Viewer, an FDA-approved device that measures tissue oxygenation at the cellular level. The device's output, the Brain Metabolic Score (BMS), is essential for Bioxytran's acellular oxygen carrier (AOC) molecule, BXT-25, which is being developed for ischemic stroke and Alzheimer's disease treatments. Bioxytran aims to use BXT-25 to replace hyperbaric oxygen treatment (HBOT) in clinical trials.

The book offers a comprehensive overview of how hyperbaric oxygen impacts brain biochemical and physiological responses, influencing mitochondrial activity and enhancing brain functions.

Bioxytran, Inc. (BIXT) announces a preprint in ResearchGate showing 50% lesion clearance and regression of Herpes Zoster Neuralgia within 48-72 hours using a topical Galectin-3 antagonist. The company aims to develop oral and intravenous drugs to treat viral diseases, highlighting the potential of this new therapy in managing shingles outbreaks.

Bioxytran, Inc. (BIXT) announces the first patients treated with ProLectin-M in a dose optimization trial to develop an antiviral drug made of sugars. The drug shows promise as a treatment for COVID-19 and other upper respiratory infections. The company plans to conduct a Phase 3 trial in India and additional studies in the US. ProLectin-M has shown high efficacy in previous clinical trials, with potential broad-spectrum antiviral capabilities. The drug targets a new binding region on virus spike proteins, offering a novel approach to viral neutralization.

Bioxytran, a clinical stage biotechnology company, has announced that its patent application for lectin-binding carbohydrates to treat viral infections has been published by the US Patent and Trademark Office. The pending patent covers the use of combinations of antiviral complex carbohydrate drugs to treat over 60 named viruses. This patent represents a new direction in antiviral therapies and has potentially wide-reaching implications.

Bioxytran, Inc. announced that its CCO will present the company's small pharma strategy at the Emerging Growth Conference on October 5, 2023.